GlassScriptPhysician profile
Emilee M Tehrani
NPI 1073042024
$7,817.81
in general payments reported to CMS, 2019-2025
37 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,718 · 2022: $2,000 · 2023: $879 · 2024: $1,699 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.31 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,674.53 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $876.18 | 2021-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $513.80 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $467.07 | 2021-2025 | Dupixent |
| Electromed, INC. | $396.03 | 2021-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.10 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Mallinckrodt Hospital Products INC. | $337.65 | 2021-2025 | Acthar, Terlivaz |
| United Therapeutics Corporation | $308.13 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $254.15 | 2021-2025 | Glassia, Cuvitru |
| Genzyme Corporation | $249.53 | 2021-2025 | |
| Merz North America, INC. | $209.04 | 2024 | |
| Sanofi-Aventis U.S. LLC | $184.94 | 2022-2024 | |
| Amgen INC. | $184.67 | 2021-2025 | Tezspire |
| Insmed, INC. | $151.14 | 2021-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $146.97 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $129.72 | 2023-2025 | Xolair |
| Merck Sharp & Dohme LLC | $129.64 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Galderma Laboratories, L.P. | $122.18 | 2023-2025 | |
| Grifols USA, LLC | $121.52 | 2021-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $117.77 | 2021-2024 | Opsumit, Uptravi |
| Inogen, INC. | $104.35 | 2022-2025 | |
| Philips North America LLC | $100.86 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Viatris Specialty LLC | $92.48 | 2025 | Yupelri |
| Mayne Pharma Commercial LLC | $85.20 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $72.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $66.16 | 2021 | |
| Shionogi INC | $55.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.26 | 2023 | |
| Vapotherm INC | $36.02 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $31.23 | 2024 | Purified Cortrophin Gel |
| Sandoz INC. | $31.07 | 2023 | Treprostinil |
| Astellas Pharma US INC | $29.99 | 2021 | |
| Abbvie INC. | $23.65 | 2023 | |
| Vifor Pharma, INC. | $17.82 | 2025 | Veltassa |
| Covis Pharma Gmbh | $16.26 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilee Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.